A5103156025- Pulmonary Hypertension Research and Treatments
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiovascular Issues in Pregnancy
- Inflammatory mediators and NSAID effects
- Eicosanoids and Hypertension Pharmacology
- GDF15 and Related Biomarkers
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Kawasaki Disease and Coronary Complications
Renji Hospital
2009-2018
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate of oral compared placebo time to first adjudicated worsening event participants PAH who recently began approved monotherapy.Methods: In this event-driven, double-blind study, we randomly allocated 690 (1:1 ratio) receive or extended-release tablets three times daily. Eligible were using monotherapy for over 30...
Background . Pulmonary hypertension due to left ventricular heart failure with preserved ejection fraction (PH-HFpEF) is an increasingly medical problem. The aim of the study was evaluate clinical efficacy fasudil on PH-HFpEF elderly patients and figure out subtype which may be therapeutic object fasudil. Method 58 were enrolled. Patients diagnosed passive pulmonary (PPH) or reactive (RPH) by right catheterization all receiving Rho kinase inhibitor for 2 weeks. endpoint includes changes in...
<h3>Introduction</h3> Primary percutaneous coronary intervention (PCI) is the preferred treatment for patients with STEMI now. But few can receive it within 90 min recommended by guideline in real world. Early routine PCI after fibrinolysis combined lytictherapy and angioplasty, which provided rapid, complete sustained reperfusion patients. Since alteplase only specific human tissue plasminogen activator available China, trial of early thrombolysis pilot feasibility study was undertaken to...
Pulmonary arterial hypertension (PAH) is characterised by increasing pulmonary pressure, right ventricular failure, and death. The typical pathological changes include medial hypertrophy, intimal fibrosis in situ thrombosis. 5-HT other factors contributed to the development of pathologic lesions. Aspirin (ASA), platelet aggregation inhibitor, inhibits release from platelet. aim current study was determine efficacy aspirin preventing or attenuating hypertension. Sprague-Dawley (SD) rats...
Objective To examine the clinical effects of intravenous lyophilize recombinant human brain natriuretic peptide (rhBNP) in patients with refractory heart failure caused by coronary artery disease.Methods Seven disease were treated rhBNP.The rhBNP nea grade,symptoms and signs,24 hours urine output,heart rate,blood pressure central venous evaluated at 0,15,30 min 1,2,4,8,12,24,and 48 h.Serum potassium,sodium,creatinine plasma BNP before after treatment measured.Results After therapy,dyspnea...